Investor Relations

Company Overview

Avant Diagnostics, Inc. ("AVANT")(AVDX) is a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology. Avant provides personalized medicine data through its TheraLink® assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across multiple cancer types, including breast, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Theralink®, was developed to empower community physicians and clinical trial investigators with actionable information to make time sensitive treatment decisions for their patients. Theralink® was designed to inform physicians which treatments are likely to be effective for their patients at any given moment in time, and also identify which treatments are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.

Contact Information

Investor Relations
Scott VanderMeer
1050 30th Street NW Suite 107
Washington, DC 20007
T: 1-708-710-9200
F: 1-203-393-9441
scottv@avantdiagnostics.com

Sign up for email updates

Be the first to receive news and updates

Learn More